An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs
- 1 June 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 28 (3) , 468-473
- https://doi.org/10.1097/01.ftd.0000211825.57984.41
Abstract
There is an increasing uptake of TDM of antiretroviral drugs, particularly in Europe. There is consensus that current antiretroviral drugs meet most of the criteria of drugs that can be considered as candidates for a TDM strategy. This review examines the pharmacokinetic-pharmacodynamic relationship for protease inibitors and non nucleoside reverse transcriptase inhibitor, give an overview of the published randomised clinical trials and then summarises the scenarios for use of TDM. Finally the development of the inhibitory quotient (IQ) concept is discussed.Keywords
This publication has 44 references indexed in Scilit:
- Gilbert Syndrome and the Development of Antiretroviral Therapy–Associated HyperbilirubinemiaThe Journal of Infectious Diseases, 2005
- Drug–drug interactions and tolerance in combining antituberculosis and antiretroviral therapyExpert Opinion on Drug Safety, 2005
- TDM: Therapeutic Drug Measuring or Therapeutic Drug Monitoring?Therapeutic Drug Monitoring, 2005
- Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected SubjectsAntimicrobial Agents and Chemotherapy, 2005
- GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy*HIV Medicine, 2004
- Pharmacokinetics of Antiretrovirals in Pregnant WomenClinical Pharmacokinetics, 2004
- Impact of Various Antiretroviral Drugs and Their Plasma Concentrations on Plasma Lipids in Heavily Pretreated HIV-Infected PatientsHIV Research & Clinical Practice, 2003
- Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced DiseaseThe Journal of Infectious Diseases, 2003
- Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing ViremiaAntimicrobial Agents and Chemotherapy, 2002
- Pharmacokinetics of the Protease Inhibitor Indinavir in Human Immunodeficiency Virus Type 1-Infected ChildrenAntimicrobial Agents and Chemotherapy, 2001